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Abstract 
Rapitalam is a drug that is a modulator of the mglur4 receptor - a kind of metabotropic glutamate 
receptors. Into BelSU Clinical and Preclinical Studies Centre there was performed experimental 
research, which carried out the identification and quantitative assessment of alkali-labile sites and 
DNA strand breaks in leukocytes of peripheral blood of male mice treated with Rapitalam. The 
method is based on the assessment of the integrity of DNA in leukocytes of the whole blood of 
animals. Rapitalam was administered to animals orally according to 2 schemes: a single acute dose 
(413 mg/kg, which corresponds to 1/5 LD50 dose) and once daily in a therapeutic dose (3 mg/kg) 
for 4 days. For analysis we used peripheral blood of mice. As an indicator of DNA damage there 
was used the value of %TDNA. The results of this study established that the level of DNA damage 
of blood leukocytes (%TDNA) in the groups with acute dose of Rapitalam statistically significantly 
different from those values in control group of animals, indicating the presence of DNA-damaging 
activity of Rapitalam in the acute dose. Analysis of the level of DNA damage of blood leukocytes 
(%TDNA) in groups of animals treated with therapeutic dose of Rapitalam showed significant 
differences between animals treated with solvent (dimethyl sulfoxide) and animals treated with 
Rapitalam dissolved in DMSO. Conspicuous is the fact that there is observed a significant 
reduction in DNA damage in the therapeutic dose of Rapitalam as compared to the acute dose and 
the group receiving only the solvent. This suggests that Rapitalam in a therapeutic dose can 
influence on the processes of intracellular metabolism and acts as a protector. 
Key words:  Rapitalam, Parkinson's disease, metabotropic glutamate receptors, mGluR4 receptor 
modulators, DNA strand breaks in leukocytes, alkali-labile sites 
 
Introduction 
Rapitalam is a mGluR4 receptor modulator. 
Mglur4 is a kind of metabotropic glutamate 
receptors. This group of receptors, as the name 
implies, doesn’t "open" for the current of ions 
through the membrane of the neuron after activation 
and exerts its effect indirectly by intracellular signal 
molecules – second messengers. Metabotropic 
receptors are divided into three groups depending on 
their mechanism of action, homology of structure and 
list of selective ligands (1 – mGluR1, mGluR5; 2 – 
mGluR2, mGluR3; 3 – mGluR4, mGluR6, mGluR7, 
mGluR8). Groups of receptors differ in their 
mechanism of action. Receptors of the first group are 
associated with Gq-protein. Other groups of 
glutamate receptors, second and third, make with Gi-
protein. It means that the activation of these receptors 
blocks the function of adenilate cyclase, which in the 
active state converts ATP into cAMP. Consequently, 
the work of cAMP protein kinase stops and a 
phosphorylation pathway that  modify the 
homeostasis of calcium doesn’t start [1, 7]. 
Based on the foregoing, we can understand the 
differences in the effects of these receptors: activation 
receptors of 1 group leads to increasing of the activity 
of NMDA and AMPA receptors is increased (i.e. by 
increasing synaptic density), but also susceptibility to 
excitotoxicity increases; activation receptors of 2 and 3 
groups, on the contrary, leads to decrease the activity 
and density of ionotropic receptors and decreases the 
likelihood of excitotoxicity [8]. 
Thus glutamate receptors play a huge role in the 
regulation of functioning and development of the 
nervous system. For example, glutamate plays a role 
in neuronal death in hypoxia – in such circumstances, 
the glutamate transporter is not capable of reuptake 
of the neurotransmitter into the cell. Therefore, in 
condition of massive death of neuronal cells, the 
amount of the released glutamate is growing 
exponentially, causing exitotoxic excitation in still 
living neurons and leading to its death.  
Glutamatergic  system  of  the brain is one of the 
most widely specialized signaling systems in our 
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brain and nervous system, and its role is difficult to 
overestimate [9]. 
The aim of this study is the identification and 
quantitative assessment of alkali-labile sites and 
DNA strand breaks in leukocytes of peripheral blood 
of male mice treated orally with Rapitalam. 
Materials and methods  
The method is based on evaluation of DNA 
integrity in whole blood leukocytes of animals and 
humans.  
The experiment was performed on small 
laboratory rodents (males of mice), with an average 
weight of 35-40 g and 2-4 months of age. The 
animals were kept in accordance with the applicable 
Sanitary rules on the device, equipment and 
maintenance of experimental biological clinics in 
BelSU Clinical and Preclinical Studies Centre, on a 
standard diet, with 12-hour light mode, in conditions 
of free access to water and food. Obtained from the 
nursery animals were distributed in randomized 
groups of 6 individuals. As a negative control there 
was used animals that were injected solvent. The 
exposure time, the conditions of the keeping of the 
negative control animals and animals receiving the 
test substances were identical [2].  
The test pharmaceutical substance of Rapitalam 
was dissolved in dimethyl sulfoxide to final 
concentration of solvent 5%. Acute dose was 413 
mg/kg, which corresponds to 1/5 of LD50 dose 
(according to studies acute toxicity the LD50 of the 
test drug was 2066 mg/kg). The therapeutic dose was 
3 mg/kg. All solutions and suspensions were 
prepared immediately before use. Rapitalam was 
administered to animals orally in two ways, either a 
single acute dose or once a day therapeutic dose for 4 
days. The substance was administered orally. 
For analysis we used a peripheral blood of the 
mice obtained by incising the tip of the tail. The 
blood aliquots sampling (10 µl) of each animal was 
performed not later than 24 hours after the 
completion of treatment. Peripheral blood was 
sampled in tubes containing phosphate buffer (136.7 
mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM 
KH2PO4, pH 7.2-7.4)  and  1 mM  EDTA,  shook  by 
vortex   to prevent  clotting   and   immediately   used 
for preparation of agarous slides [4, 5].  
Aliquots of diluted blood were mixed with an 
equal volume of 1% low-melting agarous (“Sigma 
Chem. Co.”, USA) at a temperature of 37º C and 
applied to the prepared agarous layer. After 
hardening of the agarous, containing the cells, on top 
there was applied a new layer of 0.5 % low-melting 
agarous. The slides were placed in lysing solution 
(2.5 mol/l NаС1, 0.1 mol/l EDTA, 0.01 mol/l Tris-
HCL, pH 10, 1% Triton X-100) at 4-6°C for 1 h. 
Then the slides were transferred for 20 min in 
alkaline solution (0.3 mol/l NaON, 0.001 mol/l 
EDTA, pH >13), transferred to the electrophoresis 
chamber SE-1/S-1N (LLC “Helicon”, Russia) and 
subjected to electrophoresis in a fresh portion of the 
alkaline solution (250 ml) for 20 min at 4-6°C 
(voltage 27 V, current 260-270 mA, the strength of 
the electric field 2 V/cm). 
After electrophoresis, the slides were washed with 
distilled water and stained for 1 h in a solution 
containing 2.0 µg/ml of ethydium bromide. The 
preparations were analyzed using a fluorescence 
microscope "LUMAM I-3" ("LOMO", Saint-
Petersburg, Russia). Image capture was performed with 
a digital camera "Nikon CoolPix 995" (Japan) with the 
subsequent transfer them to the computer. The 
processing of the photomicrographs was performed 
using specialized software, where there were 
implemented the algorithms of calculation of standard 
parameters of "comet" [2]. For each experimental point 
there was taken for 6 mice and prepared 3 slides of 
whole blood from each animal and photographed at 50 
"comets" slide [3], that is, for each microslide there 
were analyzed no less than 150 DNA comets with no 
overdubs of tails. The analysis of parameters of DNA 
comets was performed with the stored digital images. 
As an indicator of DNA damage there was used the 
value of %TDNA - % DNA in the tail of the comet. 
Statistical analysis was performed using student's t-test 
(p < 0.05). The middle values presented as M ± SD. 
Research results 
Data on parameters of DNA damage for each 
mouse, established after administration of Rapitalam 
and/or 5% DMSO, are shown in tables 1 and 2. Table 
3 shows average values of DNA damage in groups 
while taking the drug and/or solvent for this drug. 
Table 1. 
The level of DNA damage in peripheral blood cells of animals after administration of acute dose of DMSO  
and/or Rapitalam (M ± SD). 
DMSO Rapitalam 
Number of the 
animal 
Number of analyzed 
cells 
%TDNA 
Number of the 
animal 
Number of analyzed 
cells 
%TDNA 
1 150 12.77±1.3 7 150 24.5±6.5 
2 150 17.75±8.4 8 150 27.37±3.5 
3 150 21.34±5.4 9 150 23.63±4.0 
4 150 19.5±2.5 10 150 24.51±5.3 
5 150 15.89±3.9 11 150 22.07±9.1 
6 150 11.81±8.5 12 150 17.39±3.8 
Note: no significant differences between the values of %TDNA for DMSO and Rapitalam from individual animals. 
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Table 2. 
The level of DNA damage in peripheral blood cells of animals after administration of the therapeutic dose 
 of DMSO and/or Rapitalam (M ± SD). 
DMSO Rapitalam 
Number of the 
animal 
Number of 
analyzed cells 
%TDNA 
Number of the 
animal 
Number of 
analyzed cells 
%TDNA 
1 150 10.69±2.4 7 150 2.06±1.6* 
2 150 16.16±5.8 8 150 3.37±1.0 
3 150 14.04±5.1 9 150 3.99±0.3 
4 150 16.34±4.4 10 150 1.22±0.6* 
5 150 26.62±5.4 11 150 1.00±0.3* 
6 150 16.78±5.5 12 150 1.56±0.5* 
Comment: * - significantly different from the value for DMSO (p < 0.05). 
Table 3. 
The influence of Rapitalam on the level of DNA damage in peripheral blood leukocytes of the mice (M ± SD). 
 
Parameters 
Acute dose, 1/5 of LD50 Therapeutic dose, 3 mg/kg 
%TDNA p %TDNA p 
Rapitalam 23.25 ± 3.35 
0.008 
2.2 ±1.22 * 
0.0009 
DMSO, 5% 16.51 ± 3.75 16.77 ± 5.3 
Note: differences between the values of %TDNA for DMSO and Rapitalam as in the acute dose and the therapeutic 
dose are significant. 
* significantly different from the value for acute dose of Rapitalam (p < 0.05). 
 
Conspicuous is the fact that there is observed a 
significant reduction in DNA damage in the 
therapeutic dose of Rapitalam as compared to the 
acute dose and the group receiving only the solvent. 
This suggests that Rapitalam in a therapeutic dose 
can influence on the processes of intracellular 
metabolism and acts as a protector. 
 
Conclusions 
1. Analysis of the level of DNA damage of blood 
leukocytes (%TDNA) in the groups with acute dose of 
Rapitalam (Table 3) showed significant differences 
between animals treated with the solvent from mice treated 
with dissolved in DMSO Rapitalam (p = 0.008). It 
indicates the presence of DNA-damaging activity of 
Rapitalam in the acute dose. 
2. Analysis of the level of DNA damage of blood 
leukocytes (%TDNA) in groups with therapeutic dose of 
Rapitalam showed significant differences between animals 
treated with the solvent and animals treated with dissolved 
in DMSO Rapitalam (p = 0.0009) (see Table. 3). 
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